Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks.
It promises to create a long sought public capital market for biotechs in China and the Asia-Pacific region, which have been shut out by revenue and profit thresholds.
But to enable a sustainable market, Hong Kong Exchanges and Clearing Ltd. (HKEX) will need to make careful decisions on how it defines quality and how many companies it clears to list. The risk is that too many failures too early could sour investor appetite in the market’s infancy.
On March 23, comments are due for the second round of the exchange’s consultation paper, issued Feb. 23, which contains proposals to amend its listing rules. This would be accomplished by creating two new chapters: one for biotechs that don’t meet current financial eligibility rules and one for companies with weighted voting rights (WVR) or dual-class equity structures. The initial version was released in December, and followed a preliminary concept paper published last June.
The aim is to finalize and implement the proposals by the end of April.
The proposals are part of a modernization campaign by the exchange aimed at keeping “new economy” companies at home.
The move will introduce a huge investor base -- comprised of institutional as well as retail capital -- to new business models and valuation paradigms, and the unfamiliar risk-reward dynamics of biotech.
HKEX is addressing the risks through a number of suitability tests, guidances, listing requirements and shareholder protections (see “Follow the Rules”).
Hong Kong Exchanges and Clearing Ltd. (HKEX) has outlined both requirements and guidelines that spell out criteria for determining suitability for public listing via its proposed biotech chapter. Stakeholders who spoke with BioCentury think the requirements are achievable for quality IPOs, but noted use of “fuzzy” language in the guidelines, for example in undefined terms such as “durable patent” and “sophisticated investor.” The requirements also aim to ensure a 25% public liquidity threshold by excluding IPO shares bought by “cornerstone investors,” defined as expert investors who receive guaranteed allocations in the IPO book building process, as well as pre-IPO investors who buy into the deal. While the restriction is analogous to limiting insider participation on a NASDAQ IPO, some stakeholders fear it could constrain book building or force unnecessary dilution on issuers. HKEX also proposed post-listing risk management measures including an accelerated de-listing process to prevent shell companies from floating indefinitely. HKEX approval also would be required